Literature DB >> 8180338

The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects.

W M Halbmayer1, A Haushofer, R Schön, M Fischer.   

Abstract

A poor anticoagulant response to activated protein C (APC) in an activated partial thromboplastin time (aPTT) assay (APC resistance) was recently reported to be a cause of familial thrombophilia. The response to APC was measured in 30 patients suffering from juvenile or recurrent stroke, in 40 patients suffering from venous thromboembolism and in 50 healthy subjects. The prevalence of APC resistance was found to be significantly higher among patients with stroke (20%, P < 0.003) and venous thrombosis (17.5%, P < 0.02) compared with the prevalence of APC resistance among normal controls (2%). In one case of venous thrombosis, the proposita's family (A) could be investigated and in five out of nine investigated members (56%) a poor or borderline response to APC was detected. The family (B) of another APC-resistant patient revealed six subjects with poor coagulation response to APC out of eight family members studied (75%). Measuring protein S activity with an automated calcium-thromboplastin-based protein S activity assay, a significant correlation (P < 0.0001) between the results of this functional protein S assay and APC resistance (represented by the ratio (Rs value) of clotting time with and without addition of activated protein C) was observed. Nine out of 14 patients (64%) with poor APC response showed protein S activities below the normal range. Assessment of protein S activity with a second protein S clotting assay using factor Va as substrate confirmed only 47% of the decreased levels of the thromboplastin-based protein S clotting assay.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8180338     DOI: 10.1097/00001721-199402000-00008

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  9 in total

1.  The Heparin Rebound Phenomenon-Does It Offer Insights Toward Understanding the Pathobiology of Coronary Thrombosis and Its Treatment?

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 2.  Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism.

Authors:  B Dahlbäck
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

3.  No Prognostic Importance of Resistance to Activated Protein C in Unstable Coronary Artery Disease Despite Signs of Thrombin Activation.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998       Impact factor: 2.300

4.  Update on antithrombotic therapy for stroke prevention in atrial fibrillation.

Authors:  Hermelinda G Abcede; Bruce Ovbiagele
Journal:  Curr Treat Options Cardiovasc Med       Date:  2010-04-10

5.  Inherited prothrombotic states and ischaemic stroke in childhood.

Authors:  V Ganesan; M A McShane; R Liesner; J Cookson; I Hann; F J Kirkham
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-10       Impact factor: 10.154

6.  Inherited resistance to activated protein C in a boy with multiple thromboses in early infancy.

Authors:  W Zenz; W Muntean; S Gallistl; B Leschnik; A Beitzke
Journal:  Eur J Pediatr       Date:  1995-04       Impact factor: 3.183

Review 7.  The Cardioprotective Signaling Activity of Activated Protein C in Heart Failure and Ischemic Heart Diseases.

Authors:  Di Ren; Hemant Giri; Ji Li; Alireza R Rezaie
Journal:  Int J Mol Sci       Date:  2019-04-10       Impact factor: 5.923

8.  American College of Medical Genetics consensus statement on factor V Leiden mutation testing.

Authors:  W W Grody; J H Griffin; A K Taylor; B R Korf; J A Heit
Journal:  Genet Med       Date:  2001 Mar-Apr       Impact factor: 8.822

9.  Inherited Thrombophilia and the Risk of Arterial Ischemic Stroke: A Systematic Review and Meta-Analysis.

Authors:  Thita Chiasakul; Elizabeth De Jesus; Jiayi Tong; Yong Chen; Mark Crowther; David Garcia; Chatree Chai-Adisaksopha; Steven R Messé; Adam Cuker
Journal:  J Am Heart Assoc       Date:  2019-09-24       Impact factor: 5.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.